Literature DB >> 21537171

Bone, fracture and frailty.

Jennifer Hoy1.   

Abstract

PURPOSE OF REVIEW: This review details recent findings from cohort studies that inform the prevalence, incidence and effects of antiretroviral therapy (ART) and HIV infection on low bone mineral density (BMD), osteoporosis and fractures in different populations of HIV-infected individuals. Although ART has been spectacularly effective in prevention of disease progression and improvement in survival, the effects of ART on bone health require more research. RECENT
FINDINGS: Both HIV infection and ART are associated with significant bone loss in HIV-infected individuals. The clinical consequence of low BMD, fragility fractures are more common in older HIV patients, but the significance of low BMD remains unclear in younger individuals. Vitamin D deficiency is common, but the prevalence is no different to the general population, and no effect on BMD has been noted in cross-sectional studies. Frailty occurs at a prevalence of about 10% and is related to impaired immunity.
SUMMARY: This review examines the contributions from recent cohort studies to the understanding of the pathogenesis of bone loss in HIV, and the complex and poorly understood relationship between the effects of HIV and that of ART on bone loss.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537171     DOI: 10.1097/COH.0b013e3283478741

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  11 in total

Review 1.  Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing.

Authors:  Anna C Hearps; Genevieve E Martin; Reena Rajasuriar; Suzanne M Crowe
Journal:  Curr HIV/AIDS Rep       Date:  2014-03       Impact factor: 5.071

Review 2.  Osteoporosis in young adults: pathophysiology, diagnosis, and management.

Authors:  S Ferrari; M L Bianchi; J A Eisman; A J Foldes; S Adami; D A Wahl; J J Stepan; M-C de Vernejoul; J-M Kaufman
Journal:  Osteoporos Int       Date:  2012-06-09       Impact factor: 4.507

3.  Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.

Authors:  Jennifer F Hoy; Birgit Grund; Mollie Roediger; Ann V Schwartz; John Shepherd; Anchalee Avihingsanon; Sharlaa Badal-Faesen; Stephane de Wit; Simone Jacoby; Alberto La Rosa; Sanjay Pujari; Mauro Schechter; David White; Nicole Wyman Engen; Kristine Ensrud; Peer D Aagaard; Andrew Carr
Journal:  J Bone Miner Res       Date:  2017-06-26       Impact factor: 6.741

4.  Changes in Bone Mineral Density, Body Composition, Vitamin D Status, and Mineral Metabolism in Urban HIV-Positive South African Women Over 12 Months.

Authors:  Matthew M Hamill; John M Pettifor; Kate A Ward; Shane A Norris; Ann Prentice
Journal:  J Bone Miner Res       Date:  2017-05-08       Impact factor: 6.741

5.  Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York.

Authors:  Candice K Kwan; Benjamin Eckhardt; Jonathan Baghdadi; Judith A Aberg
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-23       Impact factor: 2.205

6.  Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Authors:  A Carr; B Grund; J Neuhaus; A Schwartz; J I Bernardino; D White; S Badel-Faesen; A Avihingsanon; K Ensrud; J Hoy
Journal:  HIV Med       Date:  2015-04       Impact factor: 3.180

7.  Time of progression to osteopenia/osteoporosis in chronically HIV-infected patients: screening DXA scan.

Authors:  Eugenia Negredo; Anna Bonjoch; Moisés Gómez-Mateu; Carla Estany; Jordi Puig; Nuria Perez-Alvarez; Joaquin Rosales; Silvana di Gregorio; Luis del Rio; Guadalupe Gómez; Bonaventura Clotet
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

8.  Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz.

Authors:  Maryam Etminani-Esfahani; Hossein Khalili; Sirous Jafari; Alireza Abdollahi; Simin Dashti-Khavidaki
Journal:  BMC Res Notes       Date:  2012-04-26

9.  Per oral substitution with 300000 IU vitamin D (Cholecalciferol) reduces bone turnover markers in HIV-infected patients.

Authors:  Rein Jan Piso; Madeleine Rothen; Jean Pierre Rothen; Matthias Stahl; Christoph Fux
Journal:  BMC Infect Dis       Date:  2013-12-06       Impact factor: 3.090

10.  Bone Mineral Density, Body Composition, and Mineral Homeostasis Over 24 Months in Urban South African Women With HIV Exposed to Antiretroviral Therapy.

Authors:  Matthew M Hamill; John M Pettifor; Kate A Ward; Shane A Norris; Ann Prentice
Journal:  JBMR Plus       Date:  2020-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.